End-Stage Renal Disease Clinical Trial
Official title:
Retrospective Post-Market Clinical Follow-Up Study of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft in Peripheral Artery Disease, Aortic Aneurysms, and Dialysis Access
NCT number | NCT05124184 |
Other study ID # | VGP 21-01 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 24, 2022 |
Est. completion date | May 31, 2024 |
This multicenter, single-arm retrospective registry (chart review) is being conducted to confirm the clinical performance and safety of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft throughout the device functional lifetime for each indication area.
Status | Recruiting |
Enrollment | 357 |
Est. completion date | May 31, 2024 |
Est. primary completion date | May 31, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: General Inclusion Criteria 1. Patient is willing and able to provide written informed consent or consent is waived, according to national and local regulations. 2. Patient was at least 18 years of age at the time of implant. PAD Cohort Inclusion Criteria 1. Patient was treated for peripheral arterial disease or peripheral arterial aneurysm requiring bypass treated with GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft at least 5 years before site initiation. Aortic Aneurysm Cohort Inclusion Criteria 1. Patient underwent simultaneous or staged aortic aneurysm repair (open surgical AAA or TAAA) involving a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft at least 5 years before site initiation. Research device could have been used to replace or bypass either a diseased visceral branch or the aorta itself. Dialysis Access Cohort Inclusion Criteria 1. Patient required the creation of a vascular access graft for hemodialysis secondary to a diagnosis of End-Stage Renal Disease using a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft at least 2 years before site initiation with the intent to cannulate the registry device. Exclusion Criteria: General Exclusion Criteria 1. Patient was not available for follow up (on-site or remotely) at the clinical site, with the exception of death (e.g., patient lost to follow-up immediately after treatment, patients who live far away from the clinical site and are not available to share follow-up data performed locally). 2. At the time of treatment, patient had known coagulation disorders, including hypercoagulability, that were not amenable to treatment. 3. Patient was pregnant at the time of treatment. 4. Patient had known or suspected systemic infection or infection at the site of graft implantation at the time of implant. 5. Patient had a separate major interventional or surgical vascular procedure within 30 days prior to treatment. CVC catheter placement would be permitted. 6. Patient is already enrolled in this registry under a different cohort. PAD Cohort Exclusion Criteria At the time of treatment, the patient must not have met any of the following criteria: 1. Patient had percutaneous transluminal angioplasty (PTA) or stenting of the target artery at the anticipated site of the proximal or distal anastomosis within 30 days prior to the index procedure. Use of PTA or stenting during the index procedure is permitted. 2. Patient had a stroke or myocardial infarction (MI) within 6 weeks prior to the index procedure. 3. Patient has previous instance of Heparin-induced Thrombocytopenia type 2 or has known hypersensitivity to heparin. 4. Patient required composite bypass for index procedure (graft + significant length of autologous vessel). Autologous "cuffs" or patches are allowed. Aortic Aneurysm Cohort Exclusion Criteria At the time of treatment, the patient must not have met any of the following criteria: 1. Patient required emergency surgery due to aneurysm rupture. Dialysis Access Cohort Exclusion Criteria At the time of treatment, the patient must not have met any of the following criteria: 1. The patient had a previous documented and unsuccessfully treated ipsilateral central venous stenosis via imaging technique. 2. The patient was taking maintenance immunosuppressant medication at the time of implant such as rapamycin, mycophenolate or mycophenolic acid, prednisone (> 10 mg), cyclosporine, tacrolimus, or cyclophosphamide. 3. The patient has had a previous instance of Heparin-Induced Thrombocytopenia type 2 (HIT-2) or has known sensitivity to heparin. |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Unversitaire d'Angers | Angers | |
France | CHRU de Besançon | Besançon | |
France | Les Hôpitaux Universitaires de Strasbourg | Strasbourg | |
Italy | Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, SOC Chirurgia Vascolare | Ancona | |
Italy | Unità di Chirurgia Vascolare Ospedale San Raffaele | Milan | |
Italy | Chirurgia Vascolare Azienda Ospedaliera Universitaria Integrata Verona | Verona | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Clínico Universitario San Cecilio | Granada |
Lead Sponsor | Collaborator |
---|---|
W.L.Gore & Associates |
France, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PAD cohort: Primary Safety Outcome: Device-related seroma or infection | 5 years | ||
Primary | PAD cohort: Primary Performance Outcome: Secondary patency (revascularization) | 5 years | ||
Primary | Aortic Aneurysm Cohort: Primary Safety Outcome: Survival through 5 years | 5 years | ||
Primary | Aortic Aneurysm Cohort: Primary Performance Outcome: Primary patency through 5 years | 5 years | ||
Primary | Dialysis Access Cohort: Primary Safety Outcome: Device-related infection through 2 years | 2 years | ||
Primary | Dialysis Access Cohort: Useable access circuit (reported as secondary patency) through 2 years | 2 years | ||
Secondary | Peripheral Artery Disease Cohort: Limb Salvage through 1 year | 1 year | ||
Secondary | Peripheral Artery Disease Cohort: Amputation-free survival through 1 year | 1 year | ||
Secondary | Peripheral Artery Disease Cohort: Device-related Adverse Events through 1 year | 1 year | ||
Secondary | Peripheral Artery Disease Cohort: Primary Patency through 1 year | 1 year | ||
Secondary | Peripheral Artery Disease Cohort: Device-related infection requiring reoperation through 5 years | 5 years | ||
Secondary | Dialysis Access Cohort: Primary patency through 1 year | 1 year | ||
Secondary | Dialysis Access Cohort: Device-related adverse events through 1 year | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04087213 -
Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
|
N/A | |
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Completed |
NCT02237521 -
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
|
N/A | |
Withdrawn |
NCT01691196 -
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
|
||
Completed |
NCT01394341 -
Liraglutide Treatment to Patients With Severe Renal Insufficiency
|
Phase 4 | |
Active, not recruiting |
NCT00247507 -
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00307463 -
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
|
Phase 4 | |
Recruiting |
NCT00155363 -
Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis
|
Phase 4 | |
Completed |
NCT00234156 -
The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers
|
N/A | |
Completed |
NCT00586131 -
Arterial pH and Total Body Nitrogen Balances in APD
|
Phase 4 | |
Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
Recruiting |
NCT04575077 -
The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
|
||
Enrolling by invitation |
NCT05001009 -
Goals of Care Conversations Study
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Recruiting |
NCT03862859 -
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
|
Phase 4 | |
Terminated |
NCT03661229 -
Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device
|
N/A | |
Completed |
NCT03288922 -
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
|
N/A | |
Completed |
NCT02360748 -
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT02572882 -
Gut Microbiome and p-Inulin in Hemodialysis
|
N/A |